Report Library

All Reports
Hepatocellular Carcinoma (HCC) KOL Interview - US, South

September 08, 2023

This interview with a US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HCC. Treatment strategies split by disease stage, as well as unmet needs, are also discussed. Key pipeline assets highlighted include tislelizumab, camrelizumab, and rivoceranib. 

This interview was conducted on 26 July 2023. 

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only). 

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.

Indications Covered: Hepatocellular (Liver) Cancer (HCC) (Including Secondary Metastases)

 Additional Resources: